Name | Nedocromil |
Description | Nedocromil (FPL 59002) inhibits the action or formation of multiple mediators. Which including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2). |
In vitro | Nedocromil suppresses the release of histamine, LTC4, and PGD2 from mast cells challenged with antigen with IC30 values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively. It also has anti-human IgE with IC30 values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively[1]. |
In vivo | Nedocromil can obviously improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function. Nedocromil-treated diabetic mice display obviously improved heart function compared with controls. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice [2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 1 mg/ml, Sonication is recommended.
|
Keywords | Prostaglandin Receptor | FPL59002 | Inhibitor | inhibit | FPL-59002 | Leukotriene Receptor | Nedocromil | Histamine Receptor |
Inhibitors Related | Tranilast | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Rutin | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |